{"id":"NCT00361218","sponsor":"Massachusetts General Hospital","briefTitle":"Biological Markers of Response to Treatment in Major Depressive Disorder","officialTitle":"Serum Brain-Derived Neurotrophic Factor (BDNF) and QEEG as Biological Markers of Response to (Es)Citalopram Treatment in Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2006-08-08","resultsPosted":"2013-09-26","lastUpdate":"2018-05-11"},"enrollment":72,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"open-label selective serotonin reuptake inhibitor (SSRI)","otherNames":["escitalopram or citalopram"]}],"arms":[{"label":"open-label selective serotonin reuptake inhibitor (SSRI)","type":"OTHER"}],"summary":"The purpose of this study is to find out if two tests are useful in predicting whether someone with depression will get better when he or she is treated with an FDA approved antidepressant medication (either citalopram or escitalopram).","primaryOutcome":{"measure":"Serum Brain-derived Neurotrophic Factor (BDNF) Levels","timeFrame":"8 weeks","effectByArm":[{"arm":"Open-label Selective Serotonin Reuptake Inhibitor (SSRI)","deltaMin":6077.27,"sd":4371.67}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":["weight gain","lack of appetite","increase in tremors","nausea","hypomania"]}}